Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of QRH-882260 for GI Neoplasm Detection
NCT02574858Phase 1Completed
- Sponsor
- University of Michigan
- Start
- Nov 2015
- Primary completion
- Aug 2016
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of QRH-882260 in gastrointestinal neoplasms, sponsored by University of Michigan. Primary endpoints: Number of Subjects With Abnormal Lab Values at 48 hours and Number of Subjects With Abnormal EKG at 30 minutes. Started Nov 2015; status: completed.
02
Drugs
QRH-882260
03
Conditions
gastrointestinal neoplasms
Beyond the preview
Go deeper on NCT02574858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02574858.